trending Market Intelligence /marketintelligence/en/news-insights/trending/g32bJxMwrrTSKjoHmmMyog2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

SenzaGen plans Stockholm IPO

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


SenzaGen plans Stockholm IPO

SenzaGen AB is planning an IPO of its common shares on the Nasdaq First North in Stockholm.

The Lund, Sweden-based company is offering up to 4,645,000 shares to the public in Sweden and Denmark as well as institutional investors in Sweden and abroad. The shares are priced at 19.40 Swedish kronor each, corresponding to an offer amount of 90 million Swedish kronor.

Meanwhile, the part of the offer that will cater to the general public in Denmark will be limited to under €1 million.

The IPO values the company at about 210 million Swedish kronor.

The public can apply for the offer from Sept. 4 to Sept. 12, while the settlement date is Sept. 19. The first day of trading is expected to be Sept. 21, assuming the Nasdaq Stockholm AB approves the application.

SenzaGen develops tests for screening potential therapies.

As of Aug. 31, US$1 was equivalent to 7.97 Swedish kronor.